Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S

Published on 10/06/2025 at 14:07

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Value-Defensive Index	06-30	CI
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Defensive Index	06-30	CI
Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025	06-12
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	06-10	CI
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S	06-10	RE
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full Year 2025	05-07	CI
Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia	05-05	MT
Drugmaker Vanda Announces Bysanti NDA Filing	05-05	RE
Vanda Pharmaceuticals Inc. Announces Bysanti NDA Filing	05-05	CI
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder	03-31	MT
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti? for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	CI
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate	03-17	MT
Vanda Pharmaceuticals Inc. Announces the Publication of an Article Article Entitled "Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S	02-24	CI
Vanda Pharmaceuticals Inc., Q4 2024 Earnings Call, Feb 13, 2025	02-13
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	02-13	CI
Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2025 and 2030	02-13	CI
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab	02-03	CI
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab	02-03	MT
Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab	02-03	RE
US retail investors dive into tech stocks in response to DeepSeek selloff	01-30	RE
Vanda Pharmaceuticals Inc. Accepts FDA Opportunity for A Hearing on New Drug Application for Tradipitant in Gastroparesis	01-27	CI
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner	01-08	MT
Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation	12-20	MT
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	11-06	MT

VANDA PHARMACEUTICALS INC.

Stock

VNDA

US9216591084

Real-time Estimate Cboe BZX Other stock markets 16:14:28 17/07/2025 BST
4.840 ^USD	+0.62%

More quotes

Chart

Duration

Period

VNDA: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Employment figures offer some respite for the Bank of England

Results preview: Legrand accelerates

July 17, 2025 at 10:51 am

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 10:24 am

When volatility boosts US banks

July 17, 2025 at 09:42 am

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 08:20 am

The Week's Biggest Mergers Unpacked

July 16, 2025 at 03:12 pm

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 02:29 pm

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 02:23 pm

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 11:16 am

Is Scott Bessent the ideal candidate to succeed Jerome Powell?

July 16, 2025 at 11:06 am

All our articles